CENTRUM EXPERIMENTALNEJ MEDICINY SLOVENSKEJ AKADEMIE VIED, VEREJNA VYSKUMNA INSTITUCIA

Their core work

The Centre of Experimental Medicine at the Slovak Academy of Sciences is a biomedical research institute conducting laboratory-based experimental work across molecular diagnostics, toxicology, and chemical safety. In practice, they develop advanced biosensing technologies — including microfluidic systems and molecular logic gates — for detecting biological targets inside living cells, and they apply AI-driven computational methods to predict how chemicals cause toxicity without animal testing. Their contribution to consortia is wet-lab and analytical expertise: metabolomics, molecular spectroscopy, and in vitro toxicological testing that feeds into regulatory-grade risk assessments. They occupy a niche where bench science meets computational modelling, making them relevant both to bioanalytical research groups and to regulatory toxicology efforts.

What they specialise in

How they've shifted over time

Their first H2020 project (LOGIC LAB, starting 2018) was firmly in the physical chemistry of biosensing — molecular logic gates, vesicle-based carriers, optical spectroscopy, microfluidics — a technology-development focus with applications in diagnostics. By the time ONTOX started in 2021, the emphasis had shifted entirely to regulatory toxicology: predicting chemical hazards using ontologies, AI, and mechanistic (animal-free) methods. The thread connecting both periods is bioanalytical measurement — metabolomics bridges the two — but the application domain moved from novel diagnostic devices to chemical safety and EU regulatory science.

They are moving toward computational and regulatory toxicology, making them increasingly relevant to chemical, pharmaceutical, and consumer-goods sectors that need animal-free safety evidence for EU regulatory submissions.

How they like to work

They have participated exclusively as consortium partners across both projects — never as coordinator — indicating a role as a specialist contributor rather than a project driver. Their two projects are in very different thematic areas, suggesting they join consortia where their specific bench or analytical expertise is needed, rather than building a fixed research community around a single agenda. With 32 unique partners across 11 countries from just two projects, they clearly work in large, multi-actor consortia rather than tight bilateral arrangements.

Despite only two H2020 projects, the institute has accumulated 32 unique consortium partners spanning 11 countries, reflecting the large consortium sizes typical of RIA and MSCA-ITN instruments. Their network is European in scope, with no evident geographic concentration given the data available.

What sets them apart

This institute is unusual in combining molecular-level experimental biology (biosensors, microfluidics, spectroscopy) with AI-based predictive toxicology under one roof within a Slovak public research context — a combination rarely found outside larger German or Dutch institutes. For consortium builders, they offer access to Central European scientific capacity and Slovak Academy of Sciences infrastructure, which can strengthen geographic balance in EU project applications. Their ONTOX participation places them inside one of the flagship EU efforts to transform chemical risk assessment, giving them direct experience with the regulatory science agenda that will shape REACH and EFSA policy for the next decade.

Highlights from their portfolio

• ONTOX
  With the largest funding share (€371,375) and running until 2026, this project connects the institute to one of EU's most policy-relevant efforts — replacing animal toxicity testing with AI and ontology-driven models for regulatory chemical safety.
• LOGIC LAB
  An MSCA-ITN project developing molecular logic gate biosensors inside vesicles for intracellular diagnostics — an ambitious bionanotechnology concept that demonstrates the institute's capacity for fundamental, device-oriented research.